Intrinsiqq
Solid Biosciences Inc. logo

Solid Biosciences Inc. Insider Trading

SLDB

Compare
Last 12 months

Insiders sold $2.68M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2025.

Net open-market
−$2.68M
0 buys · 28 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
0 / 7
executives and directors
Last open-market buy
Mar 2025
Mar 11, 2025

Get an email when SLDB's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 1910b5-1 plan
    Gabriel Brooks
    Chief Medical Officer · sold 4,374 at $5.62
    25K
    4.3% of stake
  • Feb 1810b5-1 plan
    Alexander Cumbo
    President and CEO · sold 16,644 at $5.82
    97K
    6.6% of stake
  • Feb 1810b5-1 plan
    Jessie Hanrahan
    Chief Regulatory Officer · sold 4,134 at $5.82
    24K
    5.3% of stake
  • Feb 1810b5-1 plan
    Ilan Ganot
    Director · sold 2,658 at $5.82
    15K
    1.8% of stake
  • Feb 1810b5-1 plan
    Paul Herzich
    Chief Technology Officer · sold 3,616 at $5.82
    21K
    4.7% of stake
  • Feb 1810b5-1 plan
    David T Howton
    Chief Operating Officer · sold 7,469 at $5.82
    43K
    6.6% of stake
  • Feb 1810b5-1 plan
    Gabriel Brooks
    Chief Medical Officer · sold 0
    $0
    — of stake
  • Feb 1810b5-1 plan
    Kevin Tan
    CFO & Treasurer · sold 5,404 at $5.82
    31K
    5.2% of stake
  • Feb 410b5-1 plan
    David T Howton
    Chief Operating Officer · sold 18,894 at $6.44
    122K
    16% of stake
  • Feb 410b5-1 plan
    Alexander Cumbo
    President and CEO · sold 48,913 at $6.44
    315K
    18% of stake
  • Feb 410b5-1 plan
    Ilan Ganot
    Director · sold 7,205 at $6.44
    46K
    4.8% of stake
  • Feb 410b5-1 plan
    Kevin Tan
    CFO & Treasurer · sold 14,783 at $6.44
    95K
    14% of stake
  • Feb 410b5-1 plan
    Gabriel Brooks
    Chief Medical Officer · sold 12,616 at $6.44
    81K
    13% of stake
  • Feb 410b5-1 plan
    Jessie Hanrahan
    Chief Regulatory Officer · sold 12,348 at $6.44
    80K
    15% of stake
  • Feb 410b5-1 plan
    Paul Herzich
    Chief Technology Officer · sold 10,905 at $6.44
    70K
    14% of stake
  • Feb 210b5-1 plan
    Kevin Tan
    CFO & Treasurer · sold 26,837 at $6.44
    173K
    20% of stake
  • Feb 210b5-1 plan
    Alexander Cumbo
    President and CEO · sold 80,258 at $6.44
    517K
    23% of stake
  • Feb 210b5-1 plan
    Jessie Hanrahan
    Chief Regulatory Officer · sold 26,535 at $6.44
    171K
    24% of stake
  • Feb 210b5-1 plan
    Gabriel Brooks
    Chief Medical Officer · sold 28,335 at $6.44
    182K
    23% of stake
  • Feb 210b5-1 plan
    David T Howton
    Chief Operating Officer · sold 37,771 at $6.44
    243K
    24% of stake
  • Feb 210b5-1 plan
    Paul Herzich
    Chief Technology Officer · sold 26,250 at $6.44
    169K
    25% of stake
  • Jan 2810b5-1 plan
    Ilan Ganot
    Director · sold 191 at $6.59
    1K
    0.1% of stake
  • Jan 1310b5-1 plan
    Kevin Tan
    CFO & Treasurer · sold 5,704 at $5.27
    30K
    11% of stake
  • Jan 5No plan
    Ilan Ganot
    Director · sold 1,053 at $5.43
    6K
    0.8% of stake
  • Dec 3, 202510b5-1 plan
    David T Howton
    Chief Operating Officer · sold 4,932 at $5.11
    25K
    13% of stake
  • Dec 3, 202510b5-1 plan
    Alexander Cumbo
    President and CEO · sold 10,808 at $5.11
    55K
    12% of stake
  • Dec 3, 202510b5-1 plan
    Jessie Hanrahan
    Chief Regulatory Officer · sold 4,483 at $5.11
    23K
    14% of stake
  • Dec 3, 202510b5-1 plan
    Paul Herzich
    Chief Technology Officer · sold 2,701 at $5.11
    14K
    9.2% of stake
  • Nov 10, 2025No plan
    Ilan Ganot
    Director · sold 3,278 at $4.12
    14K
    2.5% of stake
  • Oct 20, 2025No plan
    Gabriel Brooks
    Chief Medical Officer · sold 2,895 at $5.96
    17K
    7.9% of stake
  • Mar 11, 2025
    Clare Kahn
    Director · bought 1,860 at $5.34
    10K
    169% of stake
  • Feb 19, 2025
    Joseph Edelman
    Director · bought 5,000,000 at $4.03
    $20.1M
    73% of stake
  • Feb 19, 2025
    Bcls SB Investco, LP
    Large holder · bought 1,000,000 at $4.03
    $4.03M
    25% of stake
  • Feb 18, 2025
    Robert Atchinson
    Large holder · bought 252,545 at $7.56
    $1.91M
    6.3% of stake
  • Feb 14, 202510b5-1 plan
    Jessie Hanrahan
    Chief Regulatory Officer · sold 3,079 at $3.96
    12K
    14% of stake
  • Feb 14, 202510b5-1 plan
    Gabriel Brooks
    Chief Medical Officer · sold 3,256 at $3.96
    13K
    12% of stake
  • Feb 14, 202510b5-1 plan
    Kevin Tan
    CFO & Treasurer · sold 3,164 at $3.96
    13K
    8.9% of stake
  • Feb 14, 202510b5-1 plan
    Paul Herzich
    Chief Technology Officer · sold 2,688 at $3.96
    11K
    13% of stake
  • Feb 14, 202510b5-1 plan
    Alexander Cumbo
    President and CEO · sold 11,365 at $3.96
    45K
    16% of stake
  • Feb 14, 202510b5-1 plan
    Ilan Ganot
    Director · sold 1,711 at $3.96
    7K
    1.3% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SLDB, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with SLDB

CompareIntrinsic value
TCRXTScan Therapeutics Inc.
$0.15+2.03%0
ZEOXZeo Scientifix Inc.
$0.83+1.22%40
FATEFate Therapeutics Inc.
$0.92-9.01%10
ELOXEloxx Pharmaceuticals, Inc.
$10.75+0.94%20
CGONCG Oncology, Inc.
$79.47-2.97%40
ATRAAtara Biotherapeutics, Inc.
$6.33-0.16%25
XFORX4 Pharmaceuticals Inc.
$3.00+1.35%20
CRBUCaribou Biosciences, Inc.
$0.28-8.59%10

Held by ETFs

SLDB is in 20 US ETFs. The largest of them, with SLDB's weight in each:

Spot a number that looks wrong? Check it in SLDB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing SLDB

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.